Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Recruiting 3Withdrawn 1Unknown 1Completed 1

Sponsor Class

OTHER 25OTHER_GOV 3NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 45Neoplasms 28Uterine Cervical Neoplasms 24Carcinoma, Non-Small-Cell Lung 22Prostatic Neoplasms 20Stomach Neoplasms 18Colorectal Neoplasms 18Carcinoma, Hepatocellular 16Multiple Myeloma 14Ovarian Neoplasms 11Recurrence 10Pancreatic Neoplasms 10Esophageal Squamous Cell Carcinoma 10Esophageal Neoplasms 9Leukemia, Myeloid, Acute 8Endometrial Neoplasms 8Lymphoma 7Lung Neoplasms 7Brain Neoplasms 7Liver Neoplasms 6Leukemia 6Disease 6Carcinoma, Ovarian Epithelial 6Triple Negative Breast Neoplasms 5Small Cell Lung Carcinoma 5Rectal Neoplasms 5Papillomavirus Infections 5Melanoma 5Colonic Neoplasms 5Urinary Bladder Neoplasms 4

Interventions

pertuzumab 1Trastuzumab 1Docetaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × OTHER_GOV × Pathologic Complete Response × Clear all
NCT06927180 2025-06-23

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Henan Cancer Hospital

Phase 2 Recruiting
180 enrolled
Breast

Pathologic Complete Response, Breast Neoplasms

NCT05918328 2025-03-07

Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC

Henan Cancer Hospital

Phase 2 Recruiting
610 enrolled
Breast

Pathologic Complete Response, Breast Neoplasms

NCT06276868 2024-12-17

Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer

Henan Cancer Hospital

Phase 2 Recruiting
71 enrolled
Breast

Pathologic Complete Response, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡